AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23753030
Drug: Rituximab infusions
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab infusions and intensive chemotherapy (high-dose methotrexate, fractionated ifosfamide/cyclophosphamide, other drugs in rotation, intrathecal chemoprophylaxis)
Trial: 23753030
Drug: Rituximab infusions
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab infusions and intensive chemotherapy
Trial: 23753102
Drug: Cardiorespiratory fitness
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cardiorespiratory fitness (maximum oxygen uptake, mL/kg/min) measured with a maximal cycle ergometer test
Trial: 23753102
Drug: Cardiorespiratory fitness
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cardiorespiratory fitness (maximum oxygen uptake, mL/kg/min)
Trial: 23754575
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (1.2 or 1.8 mg/kg intravenously)
Trial: 23754575
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (1.2 or 1.8 mg/kg intravenously) with rifampin (CYP3A inducer)
Trial: 23754575
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (1.2 or 1.8 mg/kg intravenously) with ketoconazole (CYP3A inhibitor)
Trial: 23756764
Drug: Lenalidomide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (10 mg, 20 mg, 25 mg) and Sorafenib (200 mg, 400 mg) given orally once daily for 28 days (1 cycle).
Trial: 23756764
Drug: Lenalidomide and
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide and Sorafenib treatment.
Trial: 23759033
Drug: Treatment-seeking overweight
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-seeking overweight youth (parent-reported HRQoL)
Trial: 23759033
Drug: Treatment-seeking overweight
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-seeking overweight youth (self-reported HRQoL)
Trial: 23759033
Drug: Treatment-seeking status
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-seeking status
Trial: 23760766
Drug: 3-week inpatient
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week inpatient program combining rehabilitative treatment and preventive, psychosocial, child-centered interventions
Trial: 23761092
Drug: Continuous intraoperative
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intraoperative optical coherence tomography (OCT) measurements of anterior lens capsule position after removing the crystalline lens and after implanting a capsular tension ring (CTR).
Trial: 23761422
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human GH (r-hGH) therapy
Trial: 23762229
Drug: Trivalent flu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent flu vaccine (AdimFlu-S®) 15 mcg of hemagglutinin for each strain/0.5 mL
Trial: 23763917
Drug: Barasertib (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barasertib (800 mg, 1000 mg, 1200 mg) plus low-dose cytosine arabinoside (LDAC) 20 mg (subcutaneous injection twice daily for 10 days) administered in 28-day cycles.
Trial: 23765437
Drug: VKA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VKA therapy
Trial: 23765437
Drug: Female gender/treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Female gender/treatment with gpIIb/IIIa-antagonists
Trial: 23768574
Drug: Sublingual allergen
RxNorm normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual allergen immunotherapy (specific dosage and duration not available)
Trial: 23769498
Drug: Target fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target fortified breast milk (fat: 4.4 g, protein: 3 g, carbohydrates: 8.8 g per 100 mL)
Trial: 23770158
Drug: Enzastaurin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin (250 mg oral, 125 mg tablets twice a day; a 1125-mg loading dose on day 1)
Trial: 23770972
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day aspirin plus 40 mg/day atorvastatin
Trial: 23773637
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (monthly pulse-cyclophosphamide + azathioprine + prednisolone)
Trial: 23774433
Drug: Telbivudine 600
RxNorm normalized name: telbivudine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 600 mg (adolescents)
Trial: 23774433
Drug: Telbivudine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 15 mg/kg (children aged 2 to 12 years)
Trial: 23774433
Drug: Telbivudine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 15 mg/kg (children 2 to 12 years)
Trial: 23775962
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg once per day or 400 mg twice per day if no initial response
Trial: 23777764
Drug: MDASI-CML administered
RxNorm normalized name: Mvasi
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: MDASI-CML administered to patients every 2 weeks for 1 year
Trial: 31665349
Drug: Arginine administration
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine administration
Trial: 23782005
Drug: ATV/RTV 300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV/RTV 300/100 mg once daily with zidovudine/lamivudine 300/150 mg twice daily
Trial: 23782005
Drug: ATV/RTV 400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV/RTV 400/100 mg once daily with zidovudine/lamivudine 300/150 mg twice daily
Trial: 23782005
Drug: ATV/RTV treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV/RTV treatment
Trial: 23782005
Drug: ATV/RTV treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV/RTV treatment of mothers
Trial: 24332241
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg
Trial: 29080970
Drug: Ibrutinib 840
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib 840 mg
Trial: 23782157
Drug: Ibrutinib, 560
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib, 560 mg daily
Trial: 23782511
Drug: BM-MSCs therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BM-MSCs therapy (5 × 10(7) cells injected twice through the hepatic artery at weeks 4 and 8)
Trial: 23782511
Drug: BM-MSCs therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BM-MSCs therapy
Trial: 23782682
Drug: Haploidentical peripheral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haploidentical peripheral blood stem cell infusions (1-2x10^8 CD3+ cells/kilogram)
Trial: 23782711
Drug: Lenalidomide plus
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide plus low-dose dexamethasone (25 mg/day, adjusted for renal function)
Trial: 23786513
Drug: Biological testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological testing for STI+
Trial: 23787555
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy (prednisone 1 mg/kg daily, max 60 mg/day) until complete remission, followed by gradual dosage reduction.
Trial: 26917438
Drug: Mechanical debridement
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical debridement and systemic antibiotics
Trial: 23790772
Drug: Neoadjuvant whole-pelvis
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant whole-pelvis radiation therapy (RT)
Trial: 23791392
Drug: EMD 525797
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMD 525797 (250, 500, 1000, or 1500 mg every 2 weeks)
Trial: 23791392
Drug: EMD 525797
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMD 525797 (500 mg cohort)
Trial: 23791541
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m² on day 1 and bortezomib 1.3 mg/m² on days 1, 4, 8, 11 every 3 weeks
Trial: 23794578
Drug: Weekly WelTel
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly WelTel SMS 'check-in'
Trial: 23795577
Drug: LDMP 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDMP 7.5 mg (single dose on day 1)
Trial: 23795577
Drug: LDMP 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDMP 7.5 mg (multiple doses, once daily for 14 days)
Trial: 23795577
Drug: LDMP 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDMP 7.5 mg
Trial: 23795661
Drug: peg-IFNα-2a 180
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peg-IFNα-2a 180 μg per week and ribavirin 1000/1200 mg daily for 48 weeks (Group A)
Trial: 23795661
Drug: peg-IFNα-2a 180
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peg-IFNα-2a 180 μg per week and ribavirin 1000/1200 mg daily for 48 weeks (Group B)
Trial: 23795661
Drug: peg-IFNα-2a 180
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peg-IFNα-2a 180 μg per week and ribavirin 1000/1200 mg daily for 24 weeks (Group C)
Trial: 23795661
Drug: HCV RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV RNA below 1000 IU/mL by day 6
Trial: 23796526
Drug: Behavioural modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural modification and risk factor treatment
Trial: 23799873
Drug: Temsirolimus added
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus added to standard therapy of Rituximab and DHAP
Trial: 23800144
Drug: Integrative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative medicine treatment approach for chronic pain
Trial: 23800355
Drug: Implementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation of one or more of 11 best practices for medication reconciliation
Trial: 23800355
Drug: Baseline data
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline data collection on unintentional medication discrepancies
Trial: 23801020
Drug: Implantable cardioverter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantable cardioverter defibrillator-only therapy
Trial: 23803225
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg every 2 weeks) and low-dose interferon-α2a (3 MIU thrice weekly)
Trial: 23805209
Drug: Concurrent partners
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent partners in the past year
Trial: 23805395
Drug: Warm water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm water infusion colonoscopy
Trial: 23809138
Drug: Intensive lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive lipid-lowering therapy with atorvastatin 40 mg and ezetimibe 10 mg
Trial: 23809766
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg once daily in cycles of 3 weeks on/1 week off treatment until disease progression, unacceptable toxicity, death or patient/physician decision to discontinue.
Trial: 23810467
Drug: Cediranib 30
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib 30 mg daily and olaparib 200 mg BID
Trial: 23810788
Drug: Niraparib 30
RxNorm normalized name: niraparib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 30 mg/day
Trial: 23810788
Drug: Niraparib 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 60 mg/day
Trial: 23810788
Drug: Niraparib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 400 mg/day
Trial: 23810788
Drug: Niraparib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib (various doses)
Trial: 23810788
Drug: Niraparib (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib (doses >80 mg/day)
Trial: 23810788
Drug: Niraparib (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib (doses >60 mg/day)
Trial: 23812930
Drug: Lenalidomide (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (15 mg/day on days 1-14) in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
Trial: 23812930
Drug: Lenalidomide (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (15 mg/day)
Trial: 23812932
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg intravenous every 21 days)
Trial: 23813757
Drug: Skin intrinsic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin intrinsic fluorescence (SIF) in the intensive treatment group
Trial: 23813757
Drug: Skin intrinsic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin intrinsic fluorescence (SIF) in the conventional treatment group
Trial: 23815981
Drug: FBTA05 (Bi20),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody in combination with donor lymphocyte infusion (DLI)
Trial: 23816016
Drug: Colchicine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (0.5 mg twice a day for 1 month for patients ≥70 kg; 0.5 mg once for patients <70 kg or intolerant)
Trial: 23816920
Drug: Omalizumab (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (n = 4), administered every 2-4 weeks over 24 weeks
Trial: 23816920
Drug: Placebo (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (n = 4), administered every 2-4 weeks over 24 weeks
Trial: 23816963
Drug: Afatinib 50
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib 50 mg per day
Trial: 23817375
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dolutegravir (DTG) at 50 mg daily for 5 days followed by DTG with prednisone at 60 mg daily for 10 days (5 days high-dose followed by 5-day taper)
Trial: 23817375
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dolutegravir (DTG) at 50 mg daily for 5 days
Trial: 23817721
Drug: Dendritic cell-based
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell-based vaccine targeting CSCs
Trial: 23817974
Drug: TAK-285 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-285 (400 mg twice daily)
Trial: 23818263
Drug: Nonadjuvant influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonadjuvant influenza A H1N1 vaccine in juvenile SLE patients
Trial: 23818263
Drug: Healthy controls
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy controls vaccinated with nonadjuvant influenza A H1N1 vaccine
Trial: 23820296
Drug: Conservative Treatment
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative Treatment (Control)
Trial: 23822525
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to initiation of adequate medical therapy
Trial: 26696749
Drug: Panobinostat treatment
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat treatment
Trial: 23823198
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of interleukin-16 and 10-minute Apgar score
Trial: 23824037
Drug: Citrate infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate infusion in critically ill patients with AKI
Trial: 23824037
Drug: Citrate infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate infusion in healthy volunteers
Trial: 23824363
Drug: Intensity-modulated radiotherapy
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity-modulated radiotherapy (IMRT) delivering accelerated partial breast irradiation (APBI) at a dose of 38.5 Gy in 10 equal fractions delivered twice daily.
Trial: 23824978
Drug: Cabergoline (CAB)
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline (CAB) treatment after 24 months
Trial: 23824978
Drug: Cabergoline (CAB)
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline (CAB) treatment after 60 months
Trial: 23824978
Drug: Cumulative CAB
RxNorm normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative CAB dose
Trial: 23827886
Drug: Citalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram treatment for 10 weeks
Trial: 23828252
Drug: 1,020 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,020 mg of ferumoxytol administered over 15 min
Trial: 23829485
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion of veltuzumab (80-320 mg)
Trial: 23829485
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) injections of veltuzumab (80-320 mg)
Trial: 23829485
Drug: Both IV
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both IV and SC administration of veltuzumab
Trial: 23829485
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) injections of veltuzumab
Trial: 23829485
Drug: Veltuzumab treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veltuzumab treatment
Trial: 23830159
Drug: Acetylcholine (Ach)
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcholine (Ach) infusion (10(-6) to 10(-4))
Trial: 23830159
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion (200 μg)
Trial: 23831416
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (cisplatin 80 mg/m(2) on day 1, cisplatin 70 mg/m(2) on days 8, 15, 29, 36, 43, 57, 64; doxorubicin 30 mg/m(2) on days 8, 9, 36, 37, 57, 58) followed by surgery.
Trial: 23831416
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (doxorubicin 20 mg/m(2) on days 1, 2, 22, 23, 43, 44; carboplatin AUC 6·6 mg/mL per min on days 1, 22, 43) for patients who did not receive cycle B.
Trial: 23831416
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment regimen (including preoperative and postoperative chemotherapy).
Trial: 23831756
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral ∆(9)-tetrahydrocannabinol (THC)/day
Trial: 23831756
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg oral ∆(9)-tetrahydrocannabinol (THC)/day
Trial: 23831756
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg oral ∆(9)-tetrahydrocannabinol (THC)/day
Trial: 23831756
Drug: Oral cavity
RxNorm normalized name: INVEST ANTI-NEOPLASTIC DRUGS LIP,ORAL CAVITY AND PHARYNX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cavity contamination after smoking or oromucosal spray
Trial: 23833120
Drug: Weekly low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly low-dose chloroquine (5 mg/kg)
Trial: 23837399
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine (three doses)
Trial: 23838219
Drug: Acute medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute medicine wards